Recent Finacing
Recent Raise
Isarna Therapeutics develops oligonucleotide TGF-β inhibitors and combination modalities to modulate tumor immune evasion and proliferation, operating from Munich with a U.S. office in New York.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors